Skip to main content
锦波生物 logo

锦波生物 — Investor Relations & Filings

Ticker · 920982 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2023-08-28 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920982

About 锦波生物

https://www.sxjbswyy.com/

Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of functional proteins through synthetic biology. The company is recognized for its industrialization of recombinant humanized collagen, specifically Type III collagen with a stable triple helix structure. Its core business encompasses the production of medical-grade biomaterials, functional skincare products, and medical devices used in aesthetics, wound healing, and gynecological health. By utilizing advanced protein engineering, the company provides biocompatible solutions designed for tissue repair and anti-aging applications. Its technical focus remains on the structural optimization and large-scale production of high-purity recombinant proteins to meet clinical and consumer health demands.

Recent filings

Filing Released Lang Actions
公司关于获得第三类医疗器械注册证的公告
Regulatory Filings Classification · 100% confidence The document is an announcement by Shanxi Jinbo Biopharmaceutical Co., Ltd. about obtaining a Class III medical device registration certificate issued by the National Medical Products Administration of China. It details the product name, registration number, approval date, and the impact on the company. The document is short (738 characters) and serves as a regulatory announcement about a product approval rather than a financial report or detailed corporate filing. It does not contain financial data, management changes, voting results, or other report types defined in the filing categories. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-08-28 Chinese
第三届董事会第二十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 24th meeting of the 3rd Board of Directors of Shanxi Jinbo Biopharmaceutical Co., Ltd. It details the meeting date, attendance, and voting results on several agenda items, including approval of the 2023 semi-annual report, equity distribution plan, amendments to the company charter, use of idle raised funds, and convening an extraordinary shareholders meeting. The document references other announcements where the full reports and details are published, indicating this document itself is a meeting resolution announcement rather than the reports themselves. This type of document fits the category of Board/Management Information (MANG), as it concerns board meeting decisions and management resolutions. The document length is short (2082 characters), and it does not contain full financial data or detailed reports, so it is not an Interim Report or Annual Report. Therefore, the correct classification is MANG with high confidence.
2023-08-28 Chinese
关于召开2023年第四次临时股东大会通知公告（提供网络投票）
AGM Information Classification · 95% confidence The document is a notice announcing the convening of the 2023 fourth extraordinary general meeting of shareholders (临时股东大会) for Shanxi Jinbo Biopharmaceutical Co., Ltd. It details the meeting date, voting methods (including online voting), agenda items to be discussed, registration procedures, and other logistical information. It does not contain any financial statements, audit results, or detailed financial data. It is not a report but an announcement about a shareholders meeting. The document length is 2406 characters, which is relatively short and consistent with a meeting notice. Therefore, this document fits the category of a shareholder meeting notice, which aligns best with the AGM Information (AGM-R) category, as it is related to the Annual or Extraordinary General Meeting materials and notifications.
2023-08-28 Chinese
使用闲置募集资金购买理财产品公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shanxi Jinbo Biopharmaceutical Co., Ltd. regarding the use of idle raised funds to purchase financial products. It details the amount of funds raised through a stock issuance, the usage and storage of these funds, the decision-making process for investing idle funds in low-risk financial products, and includes opinions from independent directors, the supervisory board, and the sponsoring institution. The document is focused on capital usage and financing activities related to the company's fundraising proceeds. It is not a full financial report, earnings release, or regulatory filing, but rather an update on the company's capital management and financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 3074 characters, which is consistent with an announcement rather than a full report.
2023-08-28 Chinese
第三届监事会第十八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Shanxi Jinbo Biopharmaceutical Co., Ltd. regarding the 18th meeting of the third Supervisory Board. It includes details about the meeting, attendance, and approval of several proposals including the 2023 semi-annual report, profit distribution plan, and use of idle raised funds. The document references the actual 2023 semi-annual report and other announcements published separately on the Beijing Stock Exchange information disclosure platform, indicating this document itself is not the full semi-annual report but a meeting resolution and approval announcement. The document length is short (1779 characters) and it mainly reports on the meeting decisions rather than providing substantive financial data or the full report. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a formal announcement of meeting resolutions and approvals related to financial reports and other corporate matters, but not the reports themselves.
2023-08-28 Chinese
关于拟修订《公司章程》公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed amendments to the company's Articles of Association (公司章程). It details specific changes to share capital and registered capital following a public stock issuance and listing on the Beijing Stock Exchange. The document includes references to relevant laws and regulations and states that the amendments will be submitted to the shareholders' meeting for approval. The content is regulatory in nature, announcing corporate governance changes but does not contain financial statements or detailed reports. The document length is short (835 characters), and it is an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-08-28 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.